医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

Trial

Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial

バイオテクノロジーヘルスケアヘルス一般腫瘍学臨床試験製薬　 TimeLine: Datopotamab Deruxtecan Final Overall Survival Results HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase Trial

2024年09月23日

Datopotamab Deruxtecan Showed Median Overall Survival of 14.6 Months in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Trial

2024年09月10日

Novel Computational Pathology-Based TROP2 Biomarker for Datopotamab Deruxtecan Was Predictive of Clinical Outcomes in Patients with Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Non-Small Cell Lung Cancer in TROPION-Lung01 Phase Novel Computational Pathology-Based TROP Trial

2024年09月09日

Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial

Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial

ヘルスケア腫瘍学臨床試験製薬　 TimeLine: Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase Trial

2024年09月08日

Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase Trial

2024年05月27日

ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial

ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: ENHERTU Trial

2024年04月29日

ENHERTU® Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase ENHERTU Trial

2023年10月23日

Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

ヘルスケアヘルス一般腫瘍学臨床試験製薬　 TimeLine: Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase Trial

2023年10月23日

Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with HR Positive HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase Trial

2023年10月23日

Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial

Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR Positive HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase Trial

2023年09月22日